Evaluating Tenecteplase Before Thrombectomy in Large Vessel Stroke

Acute ischemic stroke caused by large-vessel occlusion represents a major medical emergency worldwide. For many years, clinicians debated whether administering intravenous thrombolysis prior to endovascular therapy yields superior clinical benefits compared to direct mechanical intervention alone. The standard practice traditionally relied on intravenous alteplase. However, tenecteplase has emerged as a promising alternative because of its rapid single-bolus administration, higher fibrin specificity, and longer half-life. Administering tenecteplase before thrombectomy offers distinct practical advantages in busy emergency departments, especially when transferring patients between primary centers and comprehensive stroke suites.

Despite these pharmacological benefits, clinical evidence regarding whether bridging thrombolysis with tenecteplase truly outperforms mechanical thrombectomy alone has remained inconclusive. Clinicians frequently encounter dilemmas regarding potential delays, increased bleeding risks, and overall cost-effectiveness. Recent trials examined bridging strategies with conflicting findings. Therefore, evaluating real-world and trial data using robust statistical methodologies helps clarify these critical clinical questions. A recent landmark causal inference study evaluated whether tenecteplase administration prior to mechanical thrombectomy enhances recovery in patients presenting with acute anterior circulation large-vessel occlusion. The findings provide critical insights into patient selection, timing, and therapeutic outcomes.

Target Trial Emulation Design and Methodology

To address the challenges of randomized clinical trials, researchers applied a target trial emulation framework to harmonized observational data. The study analyzed individual patient data pooled from the SWIFT DIRECT and EXTEND-IA TNK (Parts 1 and 2) clinical trials. By emulating a pragmatic randomized protocol, the investigators minimized confounding by indication and baseline selection biases. Consequently, this advanced causal inference framework allowed a precise comparison between patients who received mechanical thrombectomy alone and those who received bridging tenecteplase at doses of 0.25 mg/kg or 0.40 mg/kg before mechanical thrombectomy.

Overall, the target trial included 377 eligible patients presenting with anterior circulation large-vessel occlusions within the standard therapeutic window. Among these participants, 187 patients underwent endovascular thrombectomy alone, while 190 patients received intravenous tenecteplase before thrombectomy. The researchers estimated the average causal treatment effect using inverse probability of treatment weighting and parametric G-computation. Furthermore, the primary outcome assessed functional independence at 90 days, defined as a modified Rankin Scale score of 0 to 2. Secondary endpoints evaluated ordinal shifts across the entire disability spectrum, excellent functional outcome (freedom from disability, score 0 to 1), all-cause mortality, and symptomatic intracranial hemorrhage.

Clinical Efficacy and Overall Functional Recovery

The primary analysis revealed intriguing nuances in neurologic recovery trajectories. Specifically, the administration of tenecteplase before thrombectomy did not produce a statistically significant increase in the conventional primary endpoint of functional independence at 90 days. The standardized risk difference was 0.04 with a 95% confidence interval ranging from -0.06 to 0.13. Thus, bridging therapy did not substantially alter the proportion of patients achieving a modified Rankin Scale score between 0 and 2 when evaluated as a binary threshold.

However, ordinal analysis across the entire modified Rankin Scale spectrum told a remarkably different story. Patients receiving bridging tenecteplase achieved a significant overall improvement across all disability grades, demonstrated by an adjusted common odds ratio of 1.56. In addition, the probability of achieving complete freedom from disability, defined as a modified Rankin Scale score of 0 to 1, was significantly higher in the bridging cohort, with a standardized risk difference of 0.10. Therefore, while binary cutoffs might obscure incremental clinical gains, whole-scale analysis confirms that bridging thrombolysis substantially shifts patients toward superior functional preservation and milder residual deficits.

Impact of Early Reperfusion and Time Window

Time to treatment remains the most critical determinant of clinical success in acute neurovascular interventions. The target trial emulation study conducted granular subgroup analyses to explore how symptom onset-to-treatment intervals influenced therapeutic outcomes. Remarkably, the clinical advantage of administering tenecteplase before thrombectomy was substantially magnified when clinicians delivered the thrombolytic agent early. Specifically, patients treated within 140 minutes of symptom onset exhibited a pronounced benefit, achieving an adjusted common odds ratio of 1.63 across the ordinal modified Rankin Scale.

This temporal gradient aligns closely with the fundamental pathophysiology of cerebral ischemia. In the hyperacute phase, the ischemic penumbra remains viable, and administering a rapid intravenous thrombolytic bolus can dissolve microvascular thrombi, facilitate collateral perfusion, and even achieve partial recanalization before the mechanical stent retriever engages the primary clot. Furthermore, tenecteplase may soften the proximal thrombus, thereby reducing the number of thrombectomy passes required to establish complete reperfusion. Consequently, these findings emphasize that stroke care networks must minimize door-to-needle delays aggressively to maximize the biological benefits of bridging fibrinolysis.

Safety Profile and Hemorrhagic Complications

A major concern when combining intravenous thrombolytic drugs with invasive endovascular procedures is the potential exacerbation of bleeding complications. Clinicians often fear that administering a systemic fibrinolytic agent will increase the risk of fatal symptomatic intracranial hemorrhage or cause catastrophic reperfusion injury following mechanical revascularization. Fortunately, the safety analysis from this emulated trial provides substantial reassurance for treating physicians.

The investigators observed no statistically significant differences in primary safety endpoints between the bridging tenecteplase group and the direct mechanical thrombectomy alone cohort. Rates of symptomatic intracranial hemorrhage remained comparable across both arms, indicating that tenecteplase does not compromise patient safety when applied within established clinical parameters. Similarly, 90-day all-cause mortality rates did not differ significantly between treatment strategies. Therefore, these safety data confirm that bridging with tenecteplase offers a favorable benefit-to-risk balance, allowing clinicians to pursue aggressive systemic and endovascular recanalization without fear of excessive hemorrhagic toxicity.

Clinical Implications for Emergency Stroke Care

The findings from this causal inference study carry direct implications for acute stroke systems across various healthcare settings. In regions with tiered healthcare infrastructure, such as India, where comprehensive stroke centers with interventional neuroradiology suites are concentrated in urban hubs, transfer times from community hospitals can be substantial. In such "drip-and-ship" models, administering tenecteplase before thrombectomy at the primary spoke facility provides immediate pharmacological recanalization opportunities during transit without compromising subsequent endovascular procedures.

Moreover, the single intravenous bolus administration of tenecteplase offers vital operational advantages over continuous alteplase infusions. Clinicians can administer tenecteplase within seconds, eliminating pump programming errors and avoiding cumbersome infusion equipment during ambulance transfers. Because the therapy significantly improves ordinal recovery and disability-free status without raising hemorrhage rates, emergency departments and stroke units should actively incorporate rapid tenecteplase protocols for eligible large-vessel occlusion cases. As healthcare systems strive to improve stroke survivorship, streamlining pre-thrombectomy thrombolysis remains an indispensable component of comprehensive neurointerventional protocols.

Frequently Asked Questions

Does tenecteplase before thrombectomy increase functional independence at 90 days?

The target trial emulation analysis showed that tenecteplase before thrombectomy did not significantly increase the binary rate of functional independence, defined as a modified Rankin Scale score of 0 to 2. However, it significantly improved overall functional recovery across the entire ordinal scale and increased the probability of achieving complete freedom from disability.

Why is early administration within 140 minutes critical for tenecteplase?

Administering tenecteplase within 140 minutes of stroke onset significantly magnifies clinical benefits, achieving an adjusted common odds ratio of 1.63 for functional improvement. Rapid delivery rescues vulnerable penumbral tissue, enhances collateral microvascular flow, softens clot structure, and promotes early arterial recanalization before mechanical thrombectomy can be performed in the angiosuite.

Does bridging thrombolysis with tenecteplase increase intracranial hemorrhage risk?

The causal inference study demonstrated that bridging thrombolysis with tenecteplase does not significantly increase the risk of symptomatic intracranial hemorrhage or 90-day all-cause mortality compared to thrombectomy alone. When administered according to standardized stroke protocols, tenecteplase exhibits a reassuring safety profile without elevating severe bleeding complications.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

1. Altersberger VL et al. Bridging thrombolysis with tenecteplase versus endovascular thrombectomy alone for large-vessel anterior circulation stroke: a target trial emulation analysis. J Neurol Neurosurg Psychiatry. 2025 Jul 16. doi: 10.1136/jnnp-2024-335325. PMID: 39848674.


2. Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378(17):1573-1582.


3. Qiu Z, Li F, Sang H, et al. Intravenous tenecteplase before thrombectomy in stroke. N Engl J Med. 2025;393(2):139-150.


4. Majoie CBLM, Cavalcante F, Gralla J, et al. Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: individual participant data meta-analysis of six randomised trials. Lancet. 2023;402(10406):965-974.